Prognostic factors for primary GIST: Prime time for personalized therapy?

Annals of Surgical Oncology

Volumn 15, Issue 1, 2008, Pages 4-6

  Raut, Chandrajit P ^a   Dematteo, Ronald P ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADJUVANT THERAPY; COLON; DUODENUM; EDITORIAL; EXON; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HEALTH CARE ORGANIZATION; HUMAN; ILEUM; JEJUNUM; MITOSIS; RECTUM; SMALL INTESTINE; STOMACH; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR VOLUME;

DIGESTIVE SYSTEM SURGICAL PROCEDURES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; NEOPLASM STAGING; PROGNOSIS;

EID: 38049117595     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9634-y     Document Type: Editorial

References (18)

1. DeMatteo R, Owzar K, Maki R, et al. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. Proc Am Soc Clin Oncol 2007:Abstract No 10079
2. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33(5):459-65
3. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23(2):70-83
4. Demetri GD, Benjamin RS, Blanke CD, et al. NCCN task force report: optimal management of patients with gastrointestinal stromal tumor (GIST) - update of the NCCN clinical practice guidelines. J Natl Compr Cancer Netw 2007; 5(S2):S1-S32
5. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22(18):3813-25
6. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299(5607):708-10
7. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358(9291):1421-3
8. Antonescu CR, Sommer G, Sarran L, et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 2003; 9(9):3329-37
9. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42(8):1093-103
10. Lasota J, Dansonka-Mieszkowska A, Sobin LH, Miettinen M. A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab Invest 2004; 84(7):874-83
11. Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004; 40(5):689-95
12. Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007; 14(1):14-24
13. Bonvalot S, Eldweny H, Pechoux CL, et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol 2006; 13(12):1596-603
14. DeMatteo RP, Maki RG, Singer S, et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007; 245(3):347-52
15. Gronchi A, Fiore M, Miselli F, et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 2007; 245(3):341-6
16. Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006; 24(15):2325-31
17. Rutkowski P, Nowecki Z, Nyckowski P, et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 2006; 93(4):304-11
18. Hohenberger P, Langer C, Pistorius S, et al. Indication and results of surgery following imatinib treatment of locally advanced or metastatic GI stromal tumors (GIST). J Clin Oncol 2006; 24(18S):9500